Search Genes

GET /api/v1/genes/?format=api&page=287
HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 35521,
    "next": "https://panelapp-aus.org/api/v1/genes/?format=api&page=288",
    "previous": "https://panelapp-aus.org/api/v1/genes/?format=api&page=286",
    "results": [
        {
            "gene_data": {
                "alias": [
                    "MGC34275",
                    "MGC125904",
                    "MGC125905"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3007",
                "gene_name": "dolichyl-phosphate mannosyltransferase subunit 3",
                "omim_gene": [
                    "605951"
                ],
                "alias_name": [
                    "DPM synthase complex subunit"
                ],
                "gene_symbol": "DPM3",
                "hgnc_symbol": "DPM3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:155112367-155113071",
                            "ensembl_id": "ENSG00000179085"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:155139891-155140595",
                            "ensembl_id": "ENSG00000179085"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-06-29"
            },
            "entity_type": "gene",
            "entity_name": "DPM3",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19576565",
                "28803818",
                "30931530",
                "31469168"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15, 618992",
                "Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15, 612937"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC16372",
                    "FLJ32660",
                    "CILD21"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24245",
                "gene_name": "dynein regulatory complex subunit 1",
                "omim_gene": [
                    "615288"
                ],
                "alias_name": null,
                "gene_symbol": "DRC1",
                "hgnc_symbol": "DRC1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:26624784-26679579",
                            "ensembl_id": "ENSG00000157856"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:26401916-26456711",
                            "ensembl_id": "ENSG00000157856"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2013-03-14"
            },
            "entity_type": "gene",
            "entity_name": "DRC1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31960620",
                "32108610"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ciliary dyskinesia, primary, 21, MIM# 615294"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CDHF4"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3048",
                "gene_name": "desmoglein 1",
                "omim_gene": [
                    "125670"
                ],
                "alias_name": null,
                "gene_symbol": "DSG1",
                "hgnc_symbol": "DSG1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "18:28898052-28936992",
                            "ensembl_id": "ENSG00000134760"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "18:31318089-31357029",
                            "ensembl_id": "ENSG00000134760"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1991-03-04"
            },
            "entity_type": "gene",
            "entity_name": "DSG1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26288349",
                "19558595",
                "29315490",
                "31192455",
                "23974871",
                "29229434",
                "33666035"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, AR (MIM#615508)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "D2LIC",
                    "LIC3",
                    "CGI-60",
                    "DKFZP564A033"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24595",
                "gene_name": "dynein cytoplasmic 2 light intermediate chain 1",
                "omim_gene": [
                    "617083"
                ],
                "alias_name": null,
                "gene_symbol": "DYNC2LI1",
                "hgnc_symbol": "DYNC2LI1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:44001178-44037149",
                            "ensembl_id": "ENSG00000138036"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:43774039-43810010",
                            "ensembl_id": "ENSG00000138036"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-11-29"
            },
            "entity_type": "gene",
            "entity_name": "DYNC2LI1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33030252"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services",
                "Melbourne Genomics Health Alliance Perinatal Autopsy Flagship"
            ],
            "phenotypes": [
                "Short-rib thoracic dysplasia 15 with polydactyly, MIM#617088"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ32844",
                    "DZIP2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26551",
                "gene_name": "DAZ interacting zinc finger protein 1 like",
                "omim_gene": [
                    "617570"
                ],
                "alias_name": null,
                "gene_symbol": "DZIP1L",
                "hgnc_symbol": "DZIP1L",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:137780832-137834660",
                            "ensembl_id": "ENSG00000158163"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:138061990-138115818",
                            "ensembl_id": "ENSG00000158163"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-02-04"
            },
            "entity_type": "gene",
            "entity_name": "DZIP1L",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28530676"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polycystic kidney disease 5, 617610"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ET1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3176",
                "gene_name": "endothelin 1",
                "omim_gene": [
                    "131240"
                ],
                "alias_name": null,
                "gene_symbol": "EDN1",
                "hgnc_symbol": "EDN1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:12290596-12297427",
                            "ensembl_id": "ENSG00000078401"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:12290363-12297194",
                            "ensembl_id": "ENSG00000078401"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1989-04-06"
            },
            "entity_type": "gene",
            "entity_name": "EDN1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Auriculocondylar syndrome 3, MIM# 615706"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "WAIT-1",
                    "HEED"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3188",
                "gene_name": "embryonic ectoderm development",
                "omim_gene": [
                    "605984"
                ],
                "alias_name": [
                    "WD protein associating with integrin cytoplasmic tails 1"
                ],
                "gene_symbol": "EED",
                "hgnc_symbol": "EED",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:85955586-85989855",
                            "ensembl_id": "ENSG00000074266"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:86244544-86278813",
                            "ensembl_id": "ENSG00000074266"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-12-09"
            },
            "entity_type": "gene",
            "entity_name": "EED",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25787343",
                "27193220",
                "27868325",
                "28229514"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Cohen-Gibson syndrome, MONDO:0060510",
                "Cohen-Gibson syndrome, OMIM:617561"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EEF1AL",
                    "HS1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3192",
                "gene_name": "eukaryotic translation elongation factor 1 alpha 2",
                "omim_gene": [
                    "602959"
                ],
                "alias_name": null,
                "gene_symbol": "EEF1A2",
                "hgnc_symbol": "EEF1A2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:62119366-62130505",
                            "ensembl_id": "ENSG00000101210"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:63488013-63499315",
                            "ensembl_id": "ENSG00000101210"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-08-15"
            },
            "entity_type": "gene",
            "entity_name": "EEF1A2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments",
            "publications": [
                "24697219",
                "32196822",
                "32160274",
                "32062104",
                "31893083"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal dominant 38, MIM# 616393",
                "MONDO:0014617",
                "Developmental and epileptic encephalopathy 33, MIM# 616409",
                "MONDO:0014625"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZp762C186",
                    "TANGERIN"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30682",
                "gene_name": "EH domain binding protein 1 like 1",
                "omim_gene": null,
                "alias_name": null,
                "gene_symbol": "EHBP1L1",
                "hgnc_symbol": "EHBP1L1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:65343509-65360121",
                            "ensembl_id": "ENSG00000173442"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:65576038-65592650",
                            "ensembl_id": "ENSG00000173442"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-08-26"
            },
            "entity_type": "gene",
            "entity_name": "EHBP1L1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26833786",
                "https://dmdd.org.uk/mutants/Ehbp1l1",
                "34645488"
            ],
            "evidence": [
                "Expert Review Green",
                "Literature",
                "Expert list",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "non-immune hydrops fetalis MONDO:0009369, EHBP1L1-related"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EIF2gamma",
                    "EIF2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3267",
                "gene_name": "eukaryotic translation initiation factor 2 subunit gamma",
                "omim_gene": [
                    "300161"
                ],
                "alias_name": [
                    "eukaryotic translation initiation factor 2G"
                ],
                "gene_symbol": "EIF2S3",
                "hgnc_symbol": "EIF2S3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:24072833-24096088",
                            "ensembl_id": "ENSG00000130741"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:24054716-24077971",
                            "ensembl_id": "ENSG00000130741"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-09-06"
            },
            "entity_type": "gene",
            "entity_name": "EIF2S3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23063529",
                "27333055",
                "28055140",
                "32799315"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "MEHMO syndrome, OMIM:300148",
                "MEHMO syndrome, MONDO:0010258"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CED12",
                    "ELMO-2",
                    "CED-12",
                    "KIAA1834",
                    "FLJ11656"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17233",
                "gene_name": "engulfment and cell motility 2",
                "omim_gene": [
                    "606421"
                ],
                "alias_name": null,
                "gene_symbol": "ELMO2",
                "hgnc_symbol": "ELMO2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:44994688-45061704",
                            "ensembl_id": "ENSG00000062598"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:46366049-46432985",
                            "ensembl_id": "ENSG00000062598"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-12-13"
            },
            "entity_type": "gene",
            "entity_name": "ELMO2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Vascular malformation, primary intraosseous, MIM#\t606893"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28957",
                "gene_name": "ER membrane protein complex subunit 1",
                "omim_gene": [
                    "616846"
                ],
                "alias_name": null,
                "gene_symbol": "EMC1",
                "hgnc_symbol": "EMC1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:19542158-19578046",
                            "ensembl_id": "ENSG00000127463"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:19215664-19251552",
                            "ensembl_id": "ENSG00000127463"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2012-05-23"
            },
            "entity_type": "gene",
            "entity_name": "EMC1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26942288",
                "29271071"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Cerebellar atrophy, visual impairment, and psychomotor retardation, MIM# 616875"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "C2F",
                    "NEP1",
                    "Grcc2f"
                ],
                "biotype": null,
                "hgnc_id": "HGNC:16912",
                "gene_name": "EMG1, N1-specific pseudouridine methyltransferase",
                "omim_gene": [
                    "611531"
                ],
                "alias_name": null,
                "gene_symbol": "EMG1",
                "hgnc_symbol": "EMG1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:7072408-7105520",
                            "ensembl_id": "ENSG00000126749"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:6970893-6979941",
                            "ensembl_id": "ENSG00000126749"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-01-12"
            },
            "entity_type": "gene",
            "entity_name": "EMG1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "19463982"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Bowen-Conradi syndrome, MIM#211180"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "founder"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EMAP",
                    "HuEMAP",
                    "ELP79"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3330",
                "gene_name": "echinoderm microtubule associated protein like 1",
                "omim_gene": [
                    "602033"
                ],
                "alias_name": null,
                "gene_symbol": "EML1",
                "hgnc_symbol": "EML1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:100204030-100408397",
                            "ensembl_id": "ENSG00000066629"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:99737693-99942060",
                            "ensembl_id": "ENSG00000066629"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-02-15"
            },
            "entity_type": "gene",
            "entity_name": "EML1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31710781"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Band heterotopia, OMIM:600348"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3341",
                "gene_name": "empty spiracles homeobox 2",
                "omim_gene": [
                    "600035"
                ],
                "alias_name": null,
                "gene_symbol": "EMX2",
                "hgnc_symbol": "EMX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:119301955-119309056",
                            "ensembl_id": "ENSG00000170370"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:117542444-117549546",
                            "ensembl_id": "ENSG00000170370"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-02-08"
            },
            "entity_type": "gene",
            "entity_name": "EMX2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "8528262",
                "9359037",
                "9153481",
                "9153481",
                "18409201"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Schizencephaly, MIM# 269160"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [
                "disputed"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ36147",
                    "XTP7"
                ],
                "biotype": null,
                "hgnc_id": "HGNC:30162",
                "gene_name": "exocyst complex component 3 like 2",
                "omim_gene": [
                    "616927"
                ],
                "alias_name": null,
                "gene_symbol": "EXOC3L2",
                "hgnc_symbol": "EXOC3L2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:45715879-45737469",
                            "ensembl_id": "ENSG00000130201"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:45212621-45245431",
                            "ensembl_id": "ENSG00000283632"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-01-19"
            },
            "entity_type": "gene",
            "entity_name": "EXOC3L2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28749478",
                "27894351",
                "30327448",
                "34974531"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Brain malformation renal syndrome, MIM# 620943"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SLAC2-B"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30578",
                "gene_name": "exophilin 5",
                "omim_gene": [
                    "612878"
                ],
                "alias_name": [
                    "synaptotagmin-like homologue lacking C2 domains b"
                ],
                "gene_symbol": "EXPH5",
                "hgnc_symbol": "EXPH5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:108376158-108464465",
                            "ensembl_id": "ENSG00000110723"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:108505431-108593738",
                            "ensembl_id": "ENSG00000110723"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-10-04"
            },
            "entity_type": "gene",
            "entity_name": "EXPH5",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23176819",
                "32176379",
                "26211931",
                "27384765",
                "27730671"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Epidermolysis bullosa simplex 4, localized or generalized intermediate, autosomal recessive, OMIM #615028"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20037"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18345",
                "gene_name": "family with sequence similarity 46 member A",
                "omim_gene": [
                    "611357"
                ],
                "alias_name": null,
                "gene_symbol": "FAM46A",
                "hgnc_symbol": "FAM46A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:82201156-82462491",
                            "ensembl_id": "ENSG00000112773"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:81491439-81752774",
                            "ensembl_id": "ENSG00000112773"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-08-26"
            },
            "entity_type": "gene",
            "entity_name": "FAM46A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29358272"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Osteogenesis imperfecta, type 18, MONDO:0044329",
                "Osteogenesis imperfecta, type XVIII, OMIM:617952"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "new gene name"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ10335",
                    "FAAP43",
                    "Pog"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20748",
                "gene_name": "Fanconi anemia complementation group L",
                "omim_gene": [
                    "608111"
                ],
                "alias_name": null,
                "gene_symbol": "FANCL",
                "hgnc_symbol": "FANCL",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:58386378-58468507",
                            "ensembl_id": "ENSG00000115392"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:58159243-58241372",
                            "ensembl_id": "ENSG00000115392"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-10-15"
            },
            "entity_type": "gene",
            "entity_name": "FANCL",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19405097",
                "25754594",
                "33394227",
                "33224012"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Fanconi anemia, complementation group L, OMIM:614083",
                "Fanconi anemia complementation group L, MONDO:0013566"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FAAP250"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23168",
                "gene_name": "Fanconi anemia complementation group M",
                "omim_gene": [
                    "609644"
                ],
                "alias_name": null,
                "gene_symbol": "FANCM",
                "hgnc_symbol": "FANCM",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:45605143-45670093",
                            "ensembl_id": "ENSG00000187790"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:45135940-45200890",
                            "ensembl_id": "ENSG00000187790"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-09-01"
            },
            "entity_type": "gene",
            "entity_name": "FANCM",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Fanconi anaemia"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "refuted"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:22788",
                "gene_name": "FEZ family zinc finger 1",
                "omim_gene": [
                    "613301"
                ],
                "alias_name": null,
                "gene_symbol": "FEZF1",
                "hgnc_symbol": "FEZF1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:121941448-121950745",
                            "ensembl_id": "ENSG00000128610"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:122301394-122310691",
                            "ensembl_id": "ENSG00000128610"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-08-15"
            },
            "entity_type": "gene",
            "entity_name": "FEZF1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hypogonadotropic hypogonadism 22, with or without anosmia, MIM#\t616030"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3687",
                "gene_name": "fibroblast growth factor 9",
                "omim_gene": [
                    "600921"
                ],
                "alias_name": [
                    "glia-activating factor"
                ],
                "gene_symbol": "FGF9",
                "hgnc_symbol": "FGF9",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "13:22245522-22278637",
                            "ensembl_id": "ENSG00000102678"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "13:21671383-21704498",
                            "ensembl_id": "ENSG00000102678"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-08-15"
            },
            "entity_type": "gene",
            "entity_name": "FGF9",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33140402",
                "28730625",
                "19589401",
                "33174625",
                "19219044",
                "28730625"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Multiple synostoses syndrome 3, OMIM # 612961",
                "Craniosynostosis"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SAC3",
                    "hSac3",
                    "dJ249I4.1",
                    "ALS11",
                    "CMT4J"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:16873",
                "gene_name": "FIG4 phosphoinositide 5-phosphatase",
                "omim_gene": [
                    "609390"
                ],
                "alias_name": null,
                "gene_symbol": "FIG4",
                "hgnc_symbol": "FIG4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:110012499-110146631",
                            "ensembl_id": "ENSG00000112367"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:109691312-109825428",
                            "ensembl_id": "ENSG00000112367"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-07-30"
            },
            "entity_type": "gene",
            "entity_name": "FIG4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23623387",
                "18758830",
                "24598713"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Yunis-Varon syndrome, OMIM:216340",
                "Yunis-Varon syndrome, MONDO:0008995",
                "?Polymicrogyria, bilateral temporooccipital, OMIM:612691",
                "Bilateral parasagittal parieto-occipital polymicrogyria, MONDO:0012986"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hFKBP65",
                    "FLJ22041",
                    "FKBP6",
                    "FLJ20683",
                    "FLJ23833"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18169",
                "gene_name": "FK506 binding protein 10",
                "omim_gene": [
                    "607063"
                ],
                "alias_name": null,
                "gene_symbol": "FKBP10",
                "hgnc_symbol": "FKBP10",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:39968932-39979465",
                            "ensembl_id": "ENSG00000141756"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:41812680-41823217",
                            "ensembl_id": "ENSG00000141756"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-03-12"
            },
            "entity_type": "gene",
            "entity_name": "FKBP10",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20696291",
                "20362275",
                "20839288",
                "21567934",
                "21567934",
                "23712425",
                "22718341"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Bruck syndrome 1, MONDO:0009806",
                "Osteogenesis imperfecta, type XI, OMIM:610968",
                "Osteogenesis imperfecta type 11, MONDO:0012592",
                "Bruck syndrome 1, OMIM:259450"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FKBP38",
                    "FKBPr38"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3724",
                "gene_name": "FK506 binding protein 8",
                "omim_gene": [
                    "604840"
                ],
                "alias_name": [
                    "FK506-binding protein 8 (38kD)"
                ],
                "gene_symbol": "FKBP8",
                "hgnc_symbol": "FKBP8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:18642561-18654887",
                            "ensembl_id": "ENSG00000105701"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:18531751-18544077",
                            "ensembl_id": "ENSG00000105701"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-10-28"
            },
            "entity_type": "gene",
            "entity_name": "FKBP8",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29261186",
                "32969478"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Spina bifida, MONDO:0008449"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14074",
                "gene_name": "formin 2",
                "omim_gene": [
                    "606373"
                ],
                "alias_name": null,
                "gene_symbol": "FMN2",
                "hgnc_symbol": "FMN2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:240177648-240638489",
                            "ensembl_id": "ENSG00000155816"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:240014348-240475189",
                            "ensembl_id": "ENSG00000155816"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-11-28"
            },
            "entity_type": "gene",
            "entity_name": "FMN2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25480035",
                "32162566",
                "24161494"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Intellectual developmental disorder, autosomal recessive 47, MIM#616193"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MSF",
                    "CIG",
                    "LETS",
                    "GFND2",
                    "FINC"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3778",
                "gene_name": "fibronectin 1",
                "omim_gene": [
                    "135600"
                ],
                "alias_name": [
                    "migration-stimulating factor",
                    "cold-insoluble globulin"
                ],
                "gene_symbol": "FN1",
                "hgnc_symbol": "FN1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:216225163-216300895",
                            "ensembl_id": "ENSG00000115414"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:215360440-215436172",
                            "ensembl_id": "ENSG00000115414"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "FN1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29100092",
                "33605604"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Spondylometaphyseal dysplasia, corner fracture type (MIM#184255)"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "BPES1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1092",
                "gene_name": "forkhead box L2",
                "omim_gene": [
                    "605597"
                ],
                "alias_name": null,
                "gene_symbol": "FOXL2",
                "hgnc_symbol": "FOXL2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:138663066-138665982",
                            "ensembl_id": "ENSG00000183770"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:138944224-138947140",
                            "ensembl_id": "ENSG00000183770"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-02-28"
            },
            "entity_type": "gene",
            "entity_name": "FOXL2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31077882",
                "18642388",
                "17089161"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Blepharophimosis, epicanthus inversus, and ptosis, type 1 with premature ovarian insufficiency (POI) and type II without POI (MIM# 110100)"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CAGH44"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:13875",
                "gene_name": "forkhead box P2",
                "omim_gene": [
                    "605317"
                ],
                "alias_name": [
                    "trinucleotide repeat containing 10",
                    "forkhead/winged-helix transcription factor",
                    "speech and language disorder 1",
                    "CAG repeat protein 44"
                ],
                "gene_symbol": "FOXP2",
                "hgnc_symbol": "FOXP2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:113726382-114333827",
                            "ensembl_id": "ENSG00000128573"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:114086327-114693772",
                            "ensembl_id": "ENSG00000128573"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-11-20"
            },
            "entity_type": "gene",
            "entity_name": "FOXP2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "15877281",
                "15983371",
                "27336128"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Speech-language disorder-1, MIM# 602081"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ40908"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20842",
                "gene_name": "forkhead box P4",
                "omim_gene": [
                    "608924"
                ],
                "alias_name": null,
                "gene_symbol": "FOXP4",
                "hgnc_symbol": "FOXP4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:41514164-41570122",
                            "ensembl_id": "ENSG00000137166"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:41546426-41602384",
                            "ensembl_id": "ENSG00000137166"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-05-28"
            },
            "entity_type": "gene",
            "entity_name": "FOXP4",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33110267"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "multiple congenital abnormalities",
                "Neurodevelopmental disorder"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0316"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29007",
                "gene_name": "FERM and PDZ domain containing 4",
                "omim_gene": [
                    "300838"
                ],
                "alias_name": null,
                "gene_symbol": "FRMPD4",
                "hgnc_symbol": "FRMPD4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:12156585-12742642",
                            "ensembl_id": "ENSG00000169933"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:12138466-12724523",
                            "ensembl_id": "ENSG00000169933"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-02-09"
            },
            "entity_type": "gene",
            "entity_name": "FRMPD4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25644381",
                "29267967"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Intellectual Disability, X-linked 104, MIM#300983"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CG-6"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1362",
                "gene_name": "ferric chelate reductase 1 like",
                "omim_gene": [
                    "604574"
                ],
                "alias_name": null,
                "gene_symbol": "FRRS1L",
                "hgnc_symbol": "FRRS1L",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:111892573-111929571",
                            "ensembl_id": "ENSG00000260230"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:109130293-109167291",
                            "ensembl_id": "ENSG00000260230"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2012-03-06"
            },
            "entity_type": "gene",
            "entity_name": "FRRS1L",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27236917",
                "27239025"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Epileptic encephalopathy, early infantile, 37, MIM#616981"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4006",
                "gene_name": "alpha-L-fucosidase 1",
                "omim_gene": [
                    "612280"
                ],
                "alias_name": [
                    "α-L-fucosidase 1",
                    "tissue fucosidase",
                    "a-L-fucosidase 1"
                ],
                "gene_symbol": "FUCA1",
                "hgnc_symbol": "FUCA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:24171567-24194784",
                            "ensembl_id": "ENSG00000179163"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:23845077-23868294",
                            "ensembl_id": "ENSG00000179163"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "FUCA1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Fucosidosis, MIM# 230000"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4019",
                "gene_name": "fucosyltransferase 8",
                "omim_gene": [
                    "602589"
                ],
                "alias_name": [
                    "alpha (1,6) fucosyltransferase"
                ],
                "gene_symbol": "FUT8",
                "hgnc_symbol": "FUT8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:65877310-66210839",
                            "ensembl_id": "ENSG00000033170"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:65410592-65744121",
                            "ensembl_id": "ENSG00000033170"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-12-23"
            },
            "entity_type": "gene",
            "entity_name": "FUT8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29304374"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation with defective fucosylation 1, OMIM:618005",
                "Congenital disorder of glycosylation with defective fucosylation 1, MONDO:0020775"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4040",
                "gene_name": "frizzled class receptor 2",
                "omim_gene": [
                    "600667"
                ],
                "alias_name": null,
                "gene_symbol": "FZD2",
                "hgnc_symbol": "FZD2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:42634925-42636907",
                            "ensembl_id": "ENSG00000180340"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:44557459-44559570",
                            "ensembl_id": "ENSG00000180340"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-07-18"
            },
            "entity_type": "gene",
            "entity_name": "FZD2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25759469",
                "30455931",
                "29383834",
                "29230162"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Autosomal dominant omodysplasia, MONDO:0008123",
                "Omodysplasia 2, OMIM:164745"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HFZ5",
                    "DKFZP434E2135"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4043",
                "gene_name": "frizzled class receptor 5",
                "omim_gene": [
                    "601723"
                ],
                "alias_name": null,
                "gene_symbol": "FZD5",
                "hgnc_symbol": "FZD5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:208627310-208634287",
                            "ensembl_id": "ENSG00000163251"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:207762586-207769563",
                            "ensembl_id": "ENSG00000163251"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-09-17"
            },
            "entity_type": "gene",
            "entity_name": "FZD5",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32737437",
                "26908622"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Microphthalmia/coloboma 11, MIM# 620731"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EJM5"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4075",
                "gene_name": "gamma-aminobutyric acid type A receptor alpha1 subunit",
                "omim_gene": [
                    "137160"
                ],
                "alias_name": [
                    "GABA(A) receptor, alpha 1"
                ],
                "gene_symbol": "GABRA1",
                "hgnc_symbol": "GABRA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:161274197-161326975",
                            "ensembl_id": "ENSG00000022355"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:161847063-161899981",
                            "ensembl_id": "ENSG00000022355"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1989-06-02"
            },
            "entity_type": "gene",
            "entity_name": "GABRA1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11992121",
                "21714819",
                "24623842",
                "30842224"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Epileptic encephalopathy, early infantile, 19 615744",
                "Rett syndrome",
                "Rett-like phenotypes",
                "idiopathic generalized Epilepsy",
                "Dravet syndrome"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4082",
                "gene_name": "gamma-aminobutyric acid type A receptor beta2 subunit",
                "omim_gene": [
                    "600232"
                ],
                "alias_name": [
                    "GABA(A) receptor, beta 2"
                ],
                "gene_symbol": "GABRB2",
                "hgnc_symbol": "GABRB2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:160715436-160976050",
                            "ensembl_id": "ENSG00000145864"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:161288429-161549044",
                            "ensembl_id": "ENSG00000145864"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-04-29"
            },
            "entity_type": "gene",
            "entity_name": "GABRB2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "29100083",
                "27789573",
                "33325057"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Developmental and epileptic encephalopathy 92 MIM#617829"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4087",
                "gene_name": "gamma-aminobutyric acid type A receptor gamma2 subunit",
                "omim_gene": [
                    "137164"
                ],
                "alias_name": [
                    "GABA(A) receptor, gamma 2"
                ],
                "gene_symbol": "GABRG2",
                "hgnc_symbol": "GABRG2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:161494546-161582542",
                            "ensembl_id": "ENSG00000113327"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:162000057-162162977",
                            "ensembl_id": "ENSG00000113327"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1991-02-26"
            },
            "entity_type": "gene",
            "entity_name": "GABRG2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11326274",
                "11326275",
                "27864268"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Epileptic encephalopathy, early infantile, 74 618396",
                "Epilepsy, generalized, with febrile seizures plus, type 3, 607681"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GalNAc-T2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4124",
                "gene_name": "polypeptide N-acetylgalactosaminyltransferase 2",
                "omim_gene": [
                    "602274"
                ],
                "alias_name": [
                    "polypeptide GalNAc transferase 2"
                ],
                "gene_symbol": "GALNT2",
                "hgnc_symbol": "GALNT2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:230193536-230417870",
                            "ensembl_id": "ENSG00000143641"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:230057990-230282124",
                            "ensembl_id": "ENSG00000143641"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1996-10-26"
            },
            "entity_type": "gene",
            "entity_name": "GALNT2",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27508872",
                "32293671"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation, type IIt OMIM:618885"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GluII",
                    "G2AN",
                    "KIAA0088",
                    "GIIA"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4138",
                "gene_name": "glucosidase II alpha subunit",
                "omim_gene": [
                    "104160"
                ],
                "alias_name": [
                    "neutral alpha-glucosidase AB"
                ],
                "gene_symbol": "GANAB",
                "hgnc_symbol": "GANAB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:62392298-62414104",
                            "ensembl_id": "ENSG00000089597"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:62624826-62646726",
                            "ensembl_id": "ENSG00000089597"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "GANAB",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polycystic kidney disease 3 with or without polycystic liver disease, MONDO:0010916",
                "Polycystic kidney disease 3, OMIM:600666"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HDR"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4172",
                "gene_name": "GATA binding protein 3",
                "omim_gene": [
                    "131320"
                ],
                "alias_name": null,
                "gene_symbol": "GATA3",
                "hgnc_symbol": "GATA3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:8095567-8117161",
                            "ensembl_id": "ENSG00000107485"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:8053604-8075198",
                            "ensembl_id": "ENSG00000107485"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-11-03"
            },
            "entity_type": "gene",
            "entity_name": "GATA3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29663634"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hypoparathyroidism, sensorineural deafness, and renal dysplasia, OMIM:146255",
                "Hypoparathyroidism-deafness-renal disease syndrome, MONDO:0007797"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GFAT",
                    "GFA",
                    "GFAT1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4241",
                "gene_name": "glutamine--fructose-6-phosphate transaminase 1",
                "omim_gene": [
                    "138292"
                ],
                "alias_name": null,
                "gene_symbol": "GFPT1",
                "hgnc_symbol": "GFPT1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:69546905-69614382",
                            "ensembl_id": "ENSG00000198380"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:69319769-69387254",
                            "ensembl_id": "ENSG00000198380"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-12-14"
            },
            "entity_type": "gene",
            "entity_name": "GFPT1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21310273",
                "30635494"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Myasthenia, congenital, 12, with tubular aggregates, OMIM:610542",
                "Congenital myasthenic syndrome 12, MONDO:0012518"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RETL1",
                    "GDNFR",
                    "GFR-ALPHA-1",
                    "RET1L",
                    "TRNR1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4243",
                "gene_name": "GDNF family receptor alpha 1",
                "omim_gene": [
                    "601496"
                ],
                "alias_name": null,
                "gene_symbol": "GFRA1",
                "hgnc_symbol": "GFRA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:117816444-118032979",
                            "ensembl_id": "ENSG00000151892"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:116056925-116273467",
                            "ensembl_id": "ENSG00000151892"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-01-17"
            },
            "entity_type": "gene",
            "entity_name": "GFRA1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33020172",
                "34737117"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Renal hypodysplasia/aplasia 4, MIM# 619887"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4317",
                "gene_name": "GLI family zinc finger 1",
                "omim_gene": [
                    "165220"
                ],
                "alias_name": null,
                "gene_symbol": "GLI1",
                "hgnc_symbol": "GLI1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:57853918-57866045",
                            "ensembl_id": "ENSG00000111087"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:57460135-57472262",
                            "ensembl_id": "ENSG00000111087"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-01-14"
            },
            "entity_type": "gene",
            "entity_name": "GLI1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "34721536",
                "31621941",
                "31549748",
                "30620395"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polydactyly, preaxial I, OMIM:174400",
                "Polydactyly, postaxial, type A8, MONDO:0029130",
                "Polydactyly, postaxial, type A8, OMIM:618123",
                "Preaxial polydactyly of fingers, MONDO:0017425"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "NPHP7"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29450",
                "gene_name": "GLIS family zinc finger 2",
                "omim_gene": [
                    "608539"
                ],
                "alias_name": [
                    "nephrocystin-7"
                ],
                "gene_symbol": "GLIS2",
                "hgnc_symbol": "GLIS2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:4364762-4389598",
                            "ensembl_id": "ENSG00000126603"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:4314761-4339597",
                            "ensembl_id": "ENSG00000126603"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-07-16"
            },
            "entity_type": "gene",
            "entity_name": "GLIS2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "17618285",
                "23559409",
                "31676329"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "KidGen_CilioNephronop v38.1.0"
            ],
            "phenotypes": [
                "Nephronophthisis 7, OMIM#611498",
                "MONDO:0012680"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SAP-3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4367",
                "gene_name": "GM2 ganglioside activator",
                "omim_gene": [
                    "613109"
                ],
                "alias_name": [
                    "cerebroside sulfate activator protein",
                    "sphingolipid activator protein 3"
                ],
                "gene_symbol": "GM2A",
                "hgnc_symbol": "GM2A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:150591711-150650001",
                            "ensembl_id": "ENSG00000196743"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:151212150-151270440",
                            "ensembl_id": "ENSG00000196743"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1986-01-01"
            },
            "entity_type": "gene",
            "entity_name": "GM2A",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28417072",
                "28192816",
                "27402091"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "GM2-gangliosidosis, AB variant MIM#272750"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Gem"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17493",
                "gene_name": "geminin, DNA replication inhibitor",
                "omim_gene": [
                    "602842"
                ],
                "alias_name": null,
                "gene_symbol": "GMNN",
                "hgnc_symbol": "GMNN",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:24775159-24786327",
                            "ensembl_id": "ENSG00000112312"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:24774931-24786099",
                            "ensembl_id": "ENSG00000112312"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-08-19"
            },
            "entity_type": "gene",
            "entity_name": "GMNN",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26637980"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Meier-Gorlin syndrome 6, OMIM:616835",
                "Meier-Gorlin syndrome 6, MONDO:0014794"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FBH",
                    "FBH2",
                    "FHH2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4379",
                "gene_name": "G protein subunit alpha 11",
                "omim_gene": [
                    "139313"
                ],
                "alias_name": null,
                "gene_symbol": "GNA11",
                "hgnc_symbol": "GNA11",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:3094408-3124002",
                            "ensembl_id": "ENSG00000088256"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:3094410-3124004",
                            "ensembl_id": "ENSG00000088256"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-07-20"
            },
            "entity_type": "gene",
            "entity_name": "GNA11",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "23802536",
                "23802516",
                "24823460",
                "26818911",
                "27334330",
                "34040639"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hypocalcemia, autosomal dominant 2 MIM#615361",
                "Hypocalciuric hypercalcemia, type II MIM#145981",
                "Congenital Haemangioma"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4382",
                "gene_name": "G protein subunit alpha 14",
                "omim_gene": [
                    "604397"
                ],
                "alias_name": null,
                "gene_symbol": "GNA14",
                "hgnc_symbol": "GNA14",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:80037995-80263223",
                            "ensembl_id": "ENSG00000156049"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:77423079-77648307",
                            "ensembl_id": "ENSG00000156049"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-06-10"
            },
            "entity_type": "gene",
            "entity_name": "GNA14",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Congenital vascular tumours"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4384",
                "gene_name": "G protein subunit alpha i1",
                "omim_gene": [
                    "139310"
                ],
                "alias_name": [
                    "Gi1 protein alpha subunit"
                ],
                "gene_symbol": "GNAI1",
                "hgnc_symbol": "GNAI1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:79763271-79848718",
                            "ensembl_id": "ENSG00000127955"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:80133955-80219402",
                            "ensembl_id": "ENSG00000127955"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1988-05-11"
            },
            "entity_type": "gene",
            "entity_name": "GNAI1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28135719",
                "33473207"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "GNAI1 syndrome",
                "Developmental delay, seizures, and hypotonia"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "G-ALPHA-q",
                    "GAQ"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4390",
                "gene_name": "G protein subunit alpha q",
                "omim_gene": [
                    "600998"
                ],
                "alias_name": null,
                "gene_symbol": "GNAQ",
                "hgnc_symbol": "GNAQ",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:80331003-80646374",
                            "ensembl_id": "ENSG00000156052"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:77716087-78031458",
                            "ensembl_id": "ENSG00000156052"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-12-15"
            },
            "entity_type": "gene",
            "entity_name": "GNAQ",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Sturge-Weber syndrome, somatic, mosaic, MIM#185300"
            ],
            "mode_of_inheritance": "Other",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GB5"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4401",
                "gene_name": "G protein subunit beta 5",
                "omim_gene": [
                    "604447"
                ],
                "alias_name": null,
                "gene_symbol": "GNB5",
                "hgnc_symbol": "GNB5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:52413117-52483566",
                            "ensembl_id": "ENSG00000069966"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:52115105-52191369",
                            "ensembl_id": "ENSG00000069966"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-07-14"
            },
            "entity_type": "gene",
            "entity_name": "GNB5",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27523599",
                "27677260",
                "28697420",
                "29368331"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "gnb5-related intellectual disability-cardiac arrhythmia syndrome MONDO:0014953",
                "Lodder-Merla syndrome, type 1, with impaired intellectual development and cardiac arrhythmia (MIM#617173)",
                "Lodder-Merla syndrome, type 2, with developmental delay and with or without cardiac arrhythmia (MIM#617182)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GAA1",
                    "hGAA1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4446",
                "gene_name": "glycosylphosphatidylinositol anchor attachment 1",
                "omim_gene": [
                    "603048"
                ],
                "alias_name": [
                    "GPI transamidase subunit"
                ],
                "gene_symbol": "GPAA1",
                "hgnc_symbol": "GPAA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:145137493-145141119",
                            "ensembl_id": "ENSG00000197858"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:144082590-144086216",
                            "ensembl_id": "ENSG00000197858"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-12-09"
            },
            "entity_type": "gene",
            "entity_name": "GPAA1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29100095"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Glycosylphosphatidylinositol biosynthesis defect 15, MIM# 617810"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4454",
                "gene_name": "glypican 6",
                "omim_gene": [
                    "604404"
                ],
                "alias_name": [
                    "glypican proteoglycan 6"
                ],
                "gene_symbol": "GPC6",
                "hgnc_symbol": "GPC6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "13:93879095-95059655",
                            "ensembl_id": "ENSG00000183098"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "13:93226842-94407401",
                            "ensembl_id": "ENSG00000183098"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-05-24"
            },
            "entity_type": "gene",
            "entity_name": "GPC6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19481194",
                "32655339"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Omodysplasia 1, OMIM:258315",
                "Autosomal recessive omodysplasia, MONDO:0009779"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "SV/CNV"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "T54",
                    "GPATC5",
                    "GPATCH5",
                    "Spp2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30677",
                "gene_name": "G-patch domain and KOW motifs",
                "omim_gene": [
                    "301003"
                ],
                "alias_name": [
                    "G patch domain containing 5"
                ],
                "gene_symbol": "GPKOW",
                "hgnc_symbol": "GPKOW",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:48970334-48980151",
                            "ensembl_id": "ENSG00000068394"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:49113389-49123801",
                            "ensembl_id": "ENSG00000068394"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-05-11"
            },
            "entity_type": "gene",
            "entity_name": "GPKOW",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28612833",
                "40221893",
                "32426895"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "syndromic disease, MONDO:0002254, GPKOW-related"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PHGPx",
                    "MCSP"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4556",
                "gene_name": "glutathione peroxidase 4",
                "omim_gene": [
                    "138322"
                ],
                "alias_name": [
                    "phospholipid hydroperoxidase"
                ],
                "gene_symbol": "GPX4",
                "hgnc_symbol": "GPX4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:1103936-1106787",
                            "ensembl_id": "ENSG00000167468"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:1103926-1106791",
                            "ensembl_id": "ENSG00000167468"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-05-03"
            },
            "entity_type": "gene",
            "entity_name": "GPX4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24706940",
                "32827718"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Spondylometaphyseal dysplasia, Sedaghatian type MIM#250220"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ13687",
                    "C18orf6"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:31042",
                "gene_name": "growth regulation by estrogen in breast cancer 1 like",
                "omim_gene": null,
                "alias_name": null,
                "gene_symbol": "GREB1L",
                "hgnc_symbol": "GREB1L",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "18:18822203-19105378",
                            "ensembl_id": "ENSG00000141449"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "18:21242242-21525417",
                            "ensembl_id": "ENSG00000141449"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2009-09-08"
            },
            "entity_type": "gene",
            "entity_name": "GREB1L",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29261186",
                "32378186",
                "31974414",
                "31424080",
                "29100091",
                "29955957",
                "32585897"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Renal hypodysplasia/aplasia 3, MIM#617805",
                "renal agenesis"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ13782",
                    "BOM"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2799",
                "gene_name": "grainyhead like transcription factor 2",
                "omim_gene": [
                    "608576"
                ],
                "alias_name": null,
                "gene_symbol": "GRHL2",
                "hgnc_symbol": "GRHL2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:102504660-102681954",
                            "ensembl_id": "ENSG00000083307"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:101492432-101669726",
                            "ensembl_id": "ENSG00000083307"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-07-11"
            },
            "entity_type": "gene",
            "entity_name": "GRHL2",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27612988",
                "19415813",
                "25152456"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ectodermal dysplasia/short stature syndrome MIM#616029"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GluN2D",
                    "EB11",
                    "NR2D"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4588",
                "gene_name": "glutamate ionotropic receptor NMDA type subunit 2D",
                "omim_gene": [
                    "602717"
                ],
                "alias_name": [
                    "N-methyl-d-aspartate receptor subunit 2D"
                ],
                "gene_symbol": "GRIN2D",
                "hgnc_symbol": "GRIN2D",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:48898132-48948188",
                            "ensembl_id": "ENSG00000105464"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:48394875-48444931",
                            "ensembl_id": "ENSG00000105464"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-07-29"
            },
            "entity_type": "gene",
            "entity_name": "GRIN2D",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "27616483",
                "30280376"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Epileptic encephalopathy, early infantile, 46, MIM# 617162",
                "intellectual disability"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GPRC1A",
                    "mGlu1",
                    "MGLUR1",
                    "PPP1R85"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4593",
                "gene_name": "glutamate metabotropic receptor 1",
                "omim_gene": [
                    "604473"
                ],
                "alias_name": [
                    "protein phosphatase 1, regulatory subunit 85"
                ],
                "gene_symbol": "GRM1",
                "hgnc_symbol": "GRM1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:146348782-146758734",
                            "ensembl_id": "ENSG00000152822"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:146027646-146437598",
                            "ensembl_id": "ENSG00000152822"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-10-21"
            },
            "entity_type": "gene",
            "entity_name": "GRM1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22901947",
                "26308914"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Spinocerebellar ataxia, autosomal recessive 13 MIM#614831"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4612",
                "gene_name": "goosecoid homeobox",
                "omim_gene": [
                    "138890"
                ],
                "alias_name": null,
                "gene_symbol": "GSC",
                "hgnc_symbol": "GSC",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:95234553-95236562",
                            "ensembl_id": "ENSG00000133937"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:94768216-94770230",
                            "ensembl_id": "ENSG00000133937"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-12-13"
            },
            "entity_type": "gene",
            "entity_name": "GSC",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24290375"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome, MONDO:0011227",
                "Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, OMIM:602471"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "eRF3b",
                    "FLJ10441"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4622",
                "gene_name": "G1 to S phase transition 2",
                "omim_gene": [
                    "300418"
                ],
                "alias_name": null,
                "gene_symbol": "GSPT2",
                "hgnc_symbol": "GSPT2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:51486481-51489324",
                            "ensembl_id": "ENSG00000189369"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:51743431-51746232",
                            "ensembl_id": "ENSG00000189369"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-05-05"
            },
            "entity_type": "gene",
            "entity_name": "GSPT2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28414775",
                "41420488"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Neurodevelopmental disorder, MONDO:0700092, GSPT2-related"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "TFIIE-B",
                    "FE",
                    "TF2E2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4651",
                "gene_name": "general transcription factor IIE subunit 2",
                "omim_gene": [
                    "189964"
                ],
                "alias_name": [
                    "TFIIE beta subunit"
                ],
                "gene_symbol": "GTF2E2",
                "hgnc_symbol": "GTF2E2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:30435835-30515768",
                            "ensembl_id": "ENSG00000197265"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:30578318-30658251",
                            "ensembl_id": "ENSG00000197265"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-08-16"
            },
            "entity_type": "gene",
            "entity_name": "GTF2E2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28973399"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Trichothiodystrophy 6, nonphotosensitive, MIM #616943"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "dJ322G13.2",
                    "ZBTB23"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15808",
                "gene_name": "GDNF inducible zinc finger protein 1",
                "omim_gene": [
                    "613842"
                ],
                "alias_name": null,
                "gene_symbol": "GZF1",
                "hgnc_symbol": "GZF1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:23342787-23353700",
                            "ensembl_id": "ENSG00000125812"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:23362182-23373063",
                            "ensembl_id": "ENSG00000125812"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-09-19"
            },
            "entity_type": "gene",
            "entity_name": "GZF1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33009817",
                "28475863"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Joint laxity, short stature, and myopia, OMIM:617662",
                "Joint laxity, short stature, and myopia, MONDO:0060556"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MTPB"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4803",
                "gene_name": "hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta",
                "omim_gene": [
                    "143450"
                ],
                "alias_name": [
                    "mitochondrial trifunctional protein, beta subunit"
                ],
                "gene_symbol": "HADHB",
                "hgnc_symbol": "HADHB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:26466038-26513336",
                            "ensembl_id": "ENSG00000138029"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:26243170-26290468",
                            "ensembl_id": "ENSG00000138029"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-12-16"
            },
            "entity_type": "gene",
            "entity_name": "HADHB",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Trifunctional protein deficiency, OMIM:609015",
                "Mitochondrial trifunctional protein deficiency, MONDO:0012172"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RPX",
                    "ANF"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4877",
                "gene_name": "HESX homeobox 1",
                "omim_gene": [
                    "601802"
                ],
                "alias_name": null,
                "gene_symbol": "HESX1",
                "hgnc_symbol": "HESX1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:57231944-57260549",
                            "ensembl_id": "ENSG00000163666"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:57197843-57226521",
                            "ensembl_id": "ENSG00000163666"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-11-19"
            },
            "entity_type": "gene",
            "entity_name": "HESX1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11136712"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Septooptic dysplasia, OMIM:182230",
                "Septooptic dysplasia, MONDO:0008428"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ32731",
                    "HGNAT"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26527",
                "gene_name": "heparan-alpha-glucosaminide N-acetyltransferase",
                "omim_gene": [
                    "610453"
                ],
                "alias_name": null,
                "gene_symbol": "HGSNAT",
                "hgnc_symbol": "HGSNAT",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:42995556-43057998",
                            "ensembl_id": "ENSG00000165102"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:43140455-43202855",
                            "ensembl_id": "ENSG00000165102"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-08-16"
            },
            "entity_type": "gene",
            "entity_name": "HGSNAT",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19479962",
                "31228227",
                "20825431",
                "20583299"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mucopolysaccharidosis type IIIC (Sanfilippo C), MIM# 252930",
                "MONDO:0009657"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "H1.4",
                    "H1e",
                    "H1s-4"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4718",
                "gene_name": "histone cluster 1 H1 family member e",
                "omim_gene": [
                    "142220"
                ],
                "alias_name": null,
                "gene_symbol": "HIST1H1E",
                "hgnc_symbol": "HIST1H1E",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:26156559-26157343",
                            "ensembl_id": "ENSG00000168298"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:26156354-26157107",
                            "ensembl_id": "ENSG00000168298"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-02-21"
            },
            "entity_type": "gene",
            "entity_name": "HIST1H1E",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28475857",
                "33270410",
                "31910894",
                "31400068"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Rahman syndrome, OMIM:617537",
                "Rahman syndrome, MONDO:0044323"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "H4/g",
                    "dJ221C16.1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:4787",
                "gene_name": "histone cluster 1 H4 family member c",
                "omim_gene": [
                    "602827"
                ],
                "alias_name": null,
                "gene_symbol": "HIST1H4C",
                "hgnc_symbol": "HIST1H4C",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:26104104-26104518",
                            "ensembl_id": "ENSG00000197061"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:26103876-26104310",
                            "ensembl_id": "ENSG00000197061"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-02-21"
            },
            "entity_type": "gene",
            "entity_name": "HIST1H4C",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28920961"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Tessadori-van Haaften neurodevelopmental syndrome 1 MIM#619758"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [
                "new gene name"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "BABL",
                    "LIPO"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5009",
                "gene_name": "high mobility group AT-hook 2",
                "omim_gene": [
                    "600698"
                ],
                "alias_name": null,
                "gene_symbol": "HMGA2",
                "hgnc_symbol": "HMGA2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:66217911-66360075",
                            "ensembl_id": "ENSG00000149948"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:65824131-65966295",
                            "ensembl_id": "ENSG00000149948"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-07-26"
            },
            "entity_type": "gene",
            "entity_name": "HMGA2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32421827",
                "29655892",
                "25809938",
                "29453418",
                "29655892",
                "28796236"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Silver-Russell syndrome 5, OMIM:618908",
                "Silver-Russell syndrome 5, MONDO:0020795"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [
                "SV/CNV"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "H6",
                    "NKX5-3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5017",
                "gene_name": "H6 family homeobox 1",
                "omim_gene": [
                    "142992"
                ],
                "alias_name": null,
                "gene_symbol": "HMX1",
                "hgnc_symbol": "HMX1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:8847802-8873543",
                            "ensembl_id": "ENSG00000215612"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:8846076-8871817",
                            "ensembl_id": "ENSG00000215612"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-12-19"
            },
            "entity_type": "gene",
            "entity_name": "HMX1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Oculoauricular syndrome, MIM#612109"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hnRNPH'",
                    "FTP3",
                    "HNRPH'"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5042",
                "gene_name": "heterogeneous nuclear ribonucleoprotein H2",
                "omim_gene": [
                    "300610"
                ],
                "alias_name": null,
                "gene_symbol": "HNRNPH2",
                "hgnc_symbol": "HNRNPH2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:100663283-100669121",
                            "ensembl_id": "ENSG00000126945"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:101408295-101414133",
                            "ensembl_id": "ENSG00000126945"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2008-04-18"
            },
            "entity_type": "gene",
            "entity_name": "HNRNPH2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "34907471",
                "33728377",
                "31670473",
                "31236915",
                "30887513"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Intellectual developmental disorder, X-linked, syndromic, Bain type MIM#300986"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5111",
                "gene_name": "homeobox B1",
                "omim_gene": [
                    "142968"
                ],
                "alias_name": null,
                "gene_symbol": "HOXB1",
                "hgnc_symbol": "HOXB1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:46605888-46608359",
                            "ensembl_id": "ENSG00000120094"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:48528526-48530997",
                            "ensembl_id": "ENSG00000120094"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1990-06-15"
            },
            "entity_type": "gene",
            "entity_name": "HOXB1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22770981",
                "26007620",
                "27144914"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Facial paresis, hereditary congenital, 3, MIM# 614744",
                "MONDO:0013880"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "4-HPPD",
                    "4HPPD",
                    "GLOD3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5147",
                "gene_name": "4-hydroxyphenylpyruvate dioxygenase",
                "omim_gene": [
                    "609695"
                ],
                "alias_name": [
                    "glyoxalase domain containing 3"
                ],
                "gene_symbol": "HPD",
                "hgnc_symbol": "HPD",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:122277433-122301502",
                            "ensembl_id": "ENSG00000158104"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:121839527-121863596",
                            "ensembl_id": "ENSG00000158104"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-12-08"
            },
            "entity_type": "gene",
            "entity_name": "HPD",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "10942115",
                "17560158",
                "27604308"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hawkinsinuria (MIM#140350), AD",
                "Tyrosinemia type III (MIM#276710), AR"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MRK",
                    "LCK2",
                    "KIAA0936",
                    "MGC46090"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:21219",
                "gene_name": "intestinal cell kinase",
                "omim_gene": [
                    "612325"
                ],
                "alias_name": [
                    "serine/threonine-protein kinase ICK",
                    "MAK-related kinase"
                ],
                "gene_symbol": "ICK",
                "hgnc_symbol": "ICK",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:52866077-52926600",
                            "ensembl_id": "ENSG00000112144"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:53001279-53061802",
                            "ensembl_id": "ENSG00000112144"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-08-21"
            },
            "entity_type": "gene",
            "entity_name": "ICK",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24853502",
                "19185282",
                "27466187",
                "27069622",
                "24797473"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Endocrine-cerebroosteodysplasia, OMIM:612651",
                "Endocrine-cerebro-osteodysplasia syndrome, MONDO:0012980"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5382",
                "gene_name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic",
                "omim_gene": [
                    "147700"
                ],
                "alias_name": null,
                "gene_symbol": "IDH1",
                "hgnc_symbol": "IDH1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:209100951-209130798",
                            "ensembl_id": "ENSG00000138413"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:208236227-208266074",
                            "ensembl_id": "ENSG00000138413"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "IDH1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22057234",
                "22057236",
                "22025298",
                "24049096",
                "34393643",
                "34588213",
                "34624834",
                "34720940"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ollier disease MONDO:0008145",
                "Maffucci syndrome MONDO:0013808"
            ],
            "mode_of_inheritance": "Other",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CGI-53",
                    "NGD5",
                    "dJ1028D15.1",
                    "NGD2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15901",
                "gene_name": "intraflagellar transport 52",
                "omim_gene": [
                    "617094"
                ],
                "alias_name": null,
                "gene_symbol": "IFT52",
                "hgnc_symbol": "IFT52",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:42219571-42275936",
                            "ensembl_id": "ENSG00000101052"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:43590931-43647296",
                            "ensembl_id": "ENSG00000101052"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-11-02"
            },
            "entity_type": "gene",
            "entity_name": "IFT52",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27466190",
                "26880018",
                "31042281",
                "30242358"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services",
                "Melbourne Genomics Health Alliance Perinatal Autopsy Flagship"
            ],
            "phenotypes": [
                "Short-rib thoracic dysplasia 16 with or without polydactyly, OMIM:617102",
                "Short-rib thoracic dysplasia 16 with or without polydactyly, MONDO:0014915"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CDV-1R",
                    "MGC4027"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14313",
                "gene_name": "intraflagellar transport 81",
                "omim_gene": [
                    "605489"
                ],
                "alias_name": null,
                "gene_symbol": "IFT81",
                "hgnc_symbol": "IFT81",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:110562140-110656602",
                            "ensembl_id": "ENSG00000122970"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:110124335-110218797",
                            "ensembl_id": "ENSG00000122970"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-11-02"
            },
            "entity_type": "gene",
            "entity_name": "IFT81",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30080953",
                "26275418",
                "32783357",
                "27666822"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Melbourne Genomics Health Alliance Perinatal Autopsy Flagship"
            ],
            "phenotypes": [
                "Short-rib thoracic dysplasia 19 with or without polydactyly, MONDO:0033485",
                "Short-rib thoracic dysplasia 19 with or without polydactyly, OMIM:617895"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MAC25",
                    "IGFBP-7",
                    "PSF",
                    "FSTL2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:5476",
                "gene_name": "insulin like growth factor binding protein 7",
                "omim_gene": [
                    "602867"
                ],
                "alias_name": null,
                "gene_symbol": "IGFBP7",
                "hgnc_symbol": "IGFBP7",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:57896939-57976551",
                            "ensembl_id": "ENSG00000163453"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:57030773-57110385",
                            "ensembl_id": "ENSG00000163453"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-03-02"
            },
            "entity_type": "gene",
            "entity_name": "IGFBP7",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "34519236",
                "31730227",
                "32429784"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Retinal arterial macroaneurysm with supravalvular pulmonic stenosis MIM#614224"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SKIP"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:33882",
                "gene_name": "inositol polyphosphate-5-phosphatase K",
                "omim_gene": [
                    "607875"
                ],
                "alias_name": [
                    "skeletal muscle and kidney enriched inositol phosphatase"
                ],
                "gene_symbol": "INPP5K",
                "hgnc_symbol": "INPP5K",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:1397865-1420182",
                            "ensembl_id": "ENSG00000132376"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:1494571-1516888",
                            "ensembl_id": "ENSG00000132376"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2008-09-09"
            },
            "entity_type": "gene",
            "entity_name": "INPP5K",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28190456",
                "28190459",
                "28940338",
                "31630891",
                "33193651",
                "33792664"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Muscular dystrophy, congenital, with cataracts and intellectual disability MIM#617404"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "IRX-2a"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14361",
                "gene_name": "iroquois homeobox 5",
                "omim_gene": [
                    "606195"
                ],
                "alias_name": null,
                "gene_symbol": "IRX5",
                "hgnc_symbol": "IRX5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:54964774-54968397",
                            "ensembl_id": "ENSG00000176842"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:54930862-54934485",
                            "ensembl_id": "ENSG00000176842"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-02-27"
            },
            "entity_type": "gene",
            "entity_name": "IRX5",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22581230",
                "27453922"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hamamy syndrome, MIM# 611174"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "AIP4"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:13890",
                "gene_name": "itchy E3 ubiquitin protein ligase",
                "omim_gene": [
                    "606409"
                ],
                "alias_name": null,
                "gene_symbol": "ITCH",
                "hgnc_symbol": "ITCH",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:32951041-33099198",
                            "ensembl_id": "ENSG00000078747"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:34363235-34511393",
                            "ensembl_id": "ENSG00000078747"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-04-27"
            },
            "entity_type": "gene",
            "entity_name": "ITCH",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20170897"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Autoimmune disease, multisystem, with facial dysmorphism, MIM#613385"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6144",
                "gene_name": "integrin subunit alpha 8",
                "omim_gene": [
                    "604063"
                ],
                "alias_name": null,
                "gene_symbol": "ITGA8",
                "hgnc_symbol": "ITGA8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:15555948-15762124",
                            "ensembl_id": "ENSG00000077943"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:15513949-15720125",
                            "ensembl_id": "ENSG00000077943"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-10-01"
            },
            "entity_type": "gene",
            "entity_name": "ITGA8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24439109",
                "9054500"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Renal hypodysplasia/aplasia 1, OMIM:191830",
                "Renal hypodysplasia/aplasia 1, MONDO:0024519"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "JAM-C",
                    "JAMC"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15532",
                "gene_name": "junctional adhesion molecule 3",
                "omim_gene": [
                    "606871"
                ],
                "alias_name": null,
                "gene_symbol": "JAM3",
                "hgnc_symbol": "JAM3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:133938820-134021896",
                            "ensembl_id": "ENSG00000166086"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:134068925-134152001",
                            "ensembl_id": "ENSG00000166086"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-04-26"
            },
            "entity_type": "gene",
            "entity_name": "JAM3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23255084",
                "21109224"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Haemorrhagic destruction of the brain, subependymal calcification, and cataracts, MIM# 613730"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6217",
                "gene_name": "katanin regulatory subunit B1",
                "omim_gene": [
                    "602703"
                ],
                "alias_name": null,
                "gene_symbol": "KATNB1",
                "hgnc_symbol": "KATNB1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:57769642-57791162",
                            "ensembl_id": "ENSG00000140854"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:57735730-57757250",
                            "ensembl_id": "ENSG00000140854"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-08-25"
            },
            "entity_type": "gene",
            "entity_name": "KATNB1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25521379",
                "26640080",
                "25521378"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Lissencephaly 6, with microcephaly, OMIM:616212, MONDO:0014534"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Kv3.3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6235",
                "gene_name": "potassium voltage-gated channel subfamily C member 3",
                "omim_gene": [
                    "176264"
                ],
                "alias_name": null,
                "gene_symbol": "KCNC3",
                "hgnc_symbol": "KCNC3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:50815194-50836772",
                            "ensembl_id": "ENSG00000131398"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:50311937-50333515",
                            "ensembl_id": "ENSG00000131398"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1991-08-13"
            },
            "entity_type": "gene",
            "entity_name": "KCNC3",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Spinocerebellar ataxia 13, MIM#605259"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Kv10.1",
                    "eag",
                    "h-eag",
                    "eag1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6250",
                "gene_name": "potassium voltage-gated channel subfamily H member 1",
                "omim_gene": [
                    "603305"
                ],
                "alias_name": null,
                "gene_symbol": "KCNH1",
                "hgnc_symbol": "KCNH1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:210856555-211307457",
                            "ensembl_id": "ENSG00000143473"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:210676823-211134180",
                            "ensembl_id": "ENSG00000143473"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-03-22"
            },
            "entity_type": "gene",
            "entity_name": "KCNH1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33811134"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Zimmermann-Laband syndrome 1, OMIM:135500"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Kir3.2",
                    "GIRK2",
                    "KATP2",
                    "BIR1",
                    "hiGIRK2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6267",
                "gene_name": "potassium voltage-gated channel subfamily J member 6",
                "omim_gene": [
                    "600877"
                ],
                "alias_name": null,
                "gene_symbol": "KCNJ6",
                "hgnc_symbol": "KCNJ6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "21:38979678-39288749",
                            "ensembl_id": "ENSG00000157542"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "21:37607376-37916446",
                            "ensembl_id": "ENSG00000157542"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-04-13"
            },
            "entity_type": "gene",
            "entity_name": "KCNJ6",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25620207",
                "29852244"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Keppen-Lubinsky syndrome, MIM# 614098",
                "MONDO:0013572"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Kir6.1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6269",
                "gene_name": "potassium voltage-gated channel subfamily J member 8",
                "omim_gene": [
                    "600935"
                ],
                "alias_name": null,
                "gene_symbol": "KCNJ8",
                "hgnc_symbol": "KCNJ8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:21917889-21928515",
                            "ensembl_id": "ENSG00000121361"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:21764955-21775581",
                            "ensembl_id": "ENSG00000121361"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-07-18"
            },
            "entity_type": "gene",
            "entity_name": "KCNJ8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Other - please provide details in the comments",
            "publications": [
                "24700710",
                "25275207",
                "24176758"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Cantu syndrome"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Kv7.5"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6299",
                "gene_name": "potassium voltage-gated channel subfamily Q member 5",
                "omim_gene": [
                    "607357"
                ],
                "alias_name": null,
                "gene_symbol": "KCNQ5",
                "hgnc_symbol": "KCNQ5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:73331520-73908574",
                            "ensembl_id": "ENSG00000185760"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:72621792-73198851",
                            "ensembl_id": "ENSG00000185760"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-08-11"
            },
            "entity_type": "gene",
            "entity_name": "KCNQ5",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28669405",
                "30359776"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal dominant 46, MIM# 617601"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0601",
                    "BHC110",
                    "LSD1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29079",
                "gene_name": "lysine demethylase 1A",
                "omim_gene": [
                    "609132"
                ],
                "alias_name": null,
                "gene_symbol": "KDM1A",
                "hgnc_symbol": "KDM1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:23345941-23410182",
                            "ensembl_id": "ENSG00000004487"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:23019448-23083689",
                            "ensembl_id": "ENSG00000004487"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2009-09-29"
            },
            "entity_type": "gene",
            "entity_name": "KDM1A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26656649",
                "24838796",
                "27094131"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Cleft palate, psychomotor retardation, and distinctive facial features 616728"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "OFIP",
                    "MNR"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29110",
                "gene_name": "KIAA0753",
                "omim_gene": [
                    "617112"
                ],
                "alias_name": [
                    "moonraker",
                    "OFD1 and FOPNL interacting protein"
                ],
                "gene_symbol": "KIAA0753",
                "hgnc_symbol": "KIAA0753",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:6481468-6544247",
                            "ensembl_id": "ENSG00000198920"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:6578148-6640927",
                            "ensembl_id": "ENSG00000198920"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-12-13"
            },
            "entity_type": "gene",
            "entity_name": "KIAA0753",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28220259",
                "29138412",
                "26643951",
                "31816441"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Orofaciodigital syndrome XV, MONDO:0014932",
                "Orofaciodigital syndrome XV, OMIM:617127",
                "Joubert syndrome"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ARMS"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29508",
                "gene_name": "kinase D interacting substrate 220",
                "omim_gene": [
                    "615759"
                ],
                "alias_name": [
                    "ankyrin repeat-rich membrane-spanning protein"
                ],
                "gene_symbol": "KIDINS220",
                "hgnc_symbol": "KIDINS220",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:8865408-8977760",
                            "ensembl_id": "ENSG00000134313"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:8721081-8837630",
                            "ensembl_id": "ENSG00000134313"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2008-11-25"
            },
            "entity_type": "gene",
            "entity_name": "KIDINS220",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33205811",
                "28934391",
                "22048169",
                "32909676"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Spastic paraplegia, intellectual disability, nystagmus, and obesity OMIM:617296",
                "cerebral ventriculomegaly",
                "limb contractures",
                "spastic paraplegia, intellectual disability, nystagmus, and obesity MONDO:0015007"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0042"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19181",
                "gene_name": "kinesin family member 14",
                "omim_gene": [
                    "611279"
                ],
                "alias_name": null,
                "gene_symbol": "KIF14",
                "hgnc_symbol": "KIF14",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:200520628-200589862",
                            "ensembl_id": "ENSG00000118193"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:200551497-200620734",
                            "ensembl_id": "ENSG00000118193"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-09-12"
            },
            "entity_type": "gene",
            "entity_name": "KIF14",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29343805",
                "24128419",
                "30388224",
                "28892560"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome, MONDO:0014552",
                "Microcephaly 20, primary, autosomal recessive, OMIM:617914",
                "Meckel syndrome 12, OMIM:616258",
                "Microcephaly 20, primary, autosomal recessive, MONDO:0054761"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HK2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6318",
                "gene_name": "kinesin family member 2A",
                "omim_gene": [
                    "602591"
                ],
                "alias_name": null,
                "gene_symbol": "KIF2A",
                "hgnc_symbol": "KIF2A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:61601989-61833076",
                            "ensembl_id": "ENSG00000068796"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:62306162-62537249",
                            "ensembl_id": "ENSG00000068796"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-09-26"
            },
            "entity_type": "gene",
            "entity_name": "KIF2A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23603762",
                "21594994",
                "27747449",
                "27896282"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Complex cortical dysplasia with other brain malformations 3, MONDO:0014170",
                "Cortical dysplasia, complex, with other brain malformations 3, OMIM:615411"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:6325",
                "gene_name": "kinesin family member 5C",
                "omim_gene": [
                    "604593"
                ],
                "alias_name": null,
                "gene_symbol": "KIF5C",
                "hgnc_symbol": "KIF5C",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:149632819-149883273",
                            "ensembl_id": "ENSG00000168280"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:148875250-149026759",
                            "ensembl_id": "ENSG00000168280"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-08-24"
            },
            "entity_type": "gene",
            "entity_name": "KIF5C",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23603762",
                "23033978",
                "32562872"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Cortical dysplasia, complex, with other brain malformations 2, OMIM:615282",
                "Complex cortical dysplasia with other brain malformations 2, MONDO:0014116"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KLHL6",
                    "SBBI26",
                    "RP42"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15646",
                "gene_name": "kelch like family member 7",
                "omim_gene": [
                    "611119"
                ],
                "alias_name": [
                    "retinitis pigmentosa 42"
                ],
                "gene_symbol": "KLHL7",
                "hgnc_symbol": "KLHL7",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:23145353-23217533",
                            "ensembl_id": "ENSG00000122550"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:23105758-23177914",
                            "ensembl_id": "ENSG00000122550"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-05-21"
            },
            "entity_type": "gene",
            "entity_name": "KLHL7",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27392078",
                "29074562"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "PERCHING syndrome, MONDO:0014890",
                "PERCHING syndrome, OMIM:617055"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0304",
                    "MLL2",
                    "TRX2",
                    "HRX2",
                    "WBP7",
                    "MLL1B",
                    "MLL4",
                    "CXXC10"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15840",
                "gene_name": "lysine methyltransferase 2B",
                "omim_gene": [
                    "606834"
                ],
                "alias_name": [
                    "myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 4"
                ],
                "gene_symbol": "KMT2B",
                "hgnc_symbol": "KMT2B",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:36208921-36229779",
                            "ensembl_id": "ENSG00000272333"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:35718019-35738878",
                            "ensembl_id": "ENSG00000272333"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2013-05-09"
            },
            "entity_type": "gene",
            "entity_name": "KMT2B",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Dystonia 28, childhood-onset, MIM#617284"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "D40",
                    "AF15Q14",
                    "CT29",
                    "KIAA1570",
                    "hKNL-1",
                    "hSpc105",
                    "PPP1R55",
                    "Spc7"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24054",
                "gene_name": "kinetochore scaffold 1",
                "omim_gene": [
                    "609173"
                ],
                "alias_name": [
                    "cancer/testis antigen 29",
                    "kinetochore null 1 homolog (C. elegans)",
                    "blinkin, bub-linking kinetochore protein",
                    "protein phosphatase 1, regulatory subunit 55"
                ],
                "gene_symbol": "KNL1",
                "hgnc_symbol": "KNL1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:40886218-40956540",
                            "ensembl_id": "ENSG00000137812"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:40594020-40664342",
                            "ensembl_id": "ENSG00000137812"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2016-06-13"
            },
            "entity_type": "gene",
            "entity_name": "KNL1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26626498",
                "26621532",
                "22983954",
                "27149178",
                "30304678",
                "27784895"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Microcephaly 4, primary, autosomal recessive, OMIM:604321",
                "Microcephaly 4, primary, autosomal recessive, MONDO:0011437"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        }
    ]
}